December 2022 in “BMC women's health” The CNC® prosthetic system improved body image in breast cancer patients with hair loss from chemotherapy but did not significantly change their psychological wellbeing.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
April 2020 in “Research Square (Research Square)” Women with PCOS may have a reduced ability to fight breast tumor cells over time.
January 2019 in “Research Square (Research Square)” The trial will test if YH0618 granule prevents hair loss in breast cancer patients during chemotherapy.
April 2016 in “Journal of The American Academy of Dermatology” Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
28 citations,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
9 citations,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
March 2023 in “JAAD case reports” March 2024 in “Frontiers in genetics” Different types of fibroblasts play specific roles in wound healing and cancer, which could help improve treatments.
February 2022 in “Research Square (Research Square)” Certain nutraceuticals may enhance hair growth without affecting the cancer-fighting properties of tamoxifen.
December 2021 in “Research Square (Research Square)” Hair growth-promoting nutraceuticals do not block the cancer-fighting effects of tamoxifen and may enhance its action.
93 citations,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
451 citations,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
37 citations,
September 2003 in “Journal of Medicinal Chemistry” A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.
35 citations,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
25 citations,
August 2006 in “Human Reproduction” Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.
21 citations,
June 2010 in “Anais Brasileiros De Dermatologia” The document reports the first Brazilian case of a girl with Becker nevus syndrome, characterized by skin changes, breast underdevelopment, and scoliosis.
7 citations,
January 2016 in “Case reports in pediatrics” A girl with Becker's nevus syndrome showed good improvement in breast development using spironolactone.
3 citations,
October 1995 in “Southern Medical Journal” Finasteride may cause breast enlargement, low testosterone a risk factor.
2 citations,
March 2023 in “Annals of Translational Medicine” The analysis shows the U.S. leads in tissue expansion research, mainly for breast reconstruction, with a slightly higher complication rate when using acellular dermal matrix.
1 citations,
February 2018 in “Journal of Nursing UFPE on line” Hair loss during breast cancer treatment affects each woman differently, influenced by her environment and family.
1 citations,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
1 citations,
June 1987 in “British journal of dermatology/British journal of dermatology, Supplement” Most patients tolerated spironolactone for acne and hirsutism despite common side effects like menstrual changes and breast tenderness.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
8 citations,
April 2013 in “Journal of The American Academy of Dermatology” Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.